spacer
home > epc > autumn 2008 > intellectual property
PUBLICATIONS
European Pharmaceutical Contractor

Intellectual Property

The continued growth and prosperity of the pharmaceutical industry relies on the exploitation of existing products and innovation. The industry faces, in particular, difficulties of competition (both lawful and unlawful), heavy regulation, consumer interest and public policy. It is vital for a pharmaceutical company to develop a strategy that protects its position in the industry, allows it to expand, maximises its investment and continues innovation whilst dealing with the competitive regulated market. Intellectual property (IP) rights are critical tools which assist pharmaceutical companies in crossing this minefield.

THE NEED FOR AN IP STRATEGY

In an industry where the cost of research and development equates to 33.3 per cent of the revenue from sales, it is crucial for businesses to protect the investment incurred in carrying out that R&D (1). IP can be a pharmaceutical company’s most valuable resource. Mismanagement and failure to protect IP can lead to serious damage to the value of a business. The right IP strategy can maximise the return on the investment and assist with sustainability and commercialisation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Bell is a Lawyer in the Commercial and Intellectual Property department at Brabners Chaffe Street LLP, Solicitors, based in their Liverpool office. Colin has extensive experience in all aspects of contentious and non-contentious IP and advises on the identification, protection, exploitation and enforcement of IP, which includes filing and prosecuting trade mark and design applications. He is also part of the biotechnology multidisciplinary team at Brabners Chaffe Street LLP.
spacer
Colin Bell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement